Statement: In the primary trial and the secondary trial the only drugs administered orally are Doxorubicin and Veliparib.
Primary_evidence: INTERVENTION 1:    Arm 1 (Paclitaxel, Carboplatin)   Patients receive paclitaxel IV and carboplatin IV on day 1 (course 1 only) or day 2 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.   Paclitaxel: Given IV   Carboplatin: Given IV   Doxorubicin: Given IV   Cyclophosphamide: Given IV INTERVENTION 2:    Arm 2 (Veliparib, Paclitaxel, Carboplatin)   Patients receive veliparib PO BID on days 1-5. Patients also receive paclitaxel IV and carboplatin IV on day 3 (course 1 only) or day 4 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.   Paclitaxel: Given IV   Carboplatin: Given IV   Doxorubicin: Given IV   Cyclophosphamide: Given IV   Veliparib: Given PO
Secondary_evidence: INTERVENTION 1:    Treatment (Enzyme Inhibitor Therapy)   Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.